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MitoTracker Deep Red (MTDR) is a relatively non-toxic, carbocyanine-based, far-red,
fluorescent probe that is routinely used to chemically mark and visualize mitochondria in
living cells. Previously, we used MTDR at low nano-molar concentrations to stain and
metabolically fractionate breast cancer cells into Mito-high and Mito-low cell sub-
populations, by flow-cytometry. Functionally, the Mito-high cell population was
specifically enriched in cancer stem cell (CSC) activity, i) showing increased levels of
ESA cell surface expression and ALDH activity, ii) elevated 3D anchorage-independent
growth, iii) larger overall cell size (>12-mm) and iv) Paclitaxel-resistance. The Mito-high cell
population also showed enhanced tumor-initiating activity, in an in vivo preclinical animal
model. Here, we explored the hypothesis that higher nano-molar concentrations of MTDR
could also be used to therapeutically target and eradicate CSCs. For this purpose, we
employed an ER(+) cell line (MCF7) and two triple negative cell lines (MDA-MB-231 and
MDA-MB-468), as model systems. Remarkably, MTDR inhibited 3D mammosphere
formation in MCF7 and MDA-MB-468 cells, with an IC-50 between 50 to 100 nM;
similar results were obtained in MDA-MB-231 cells. In addition, we now show that MTDR
exhibited near complete inhibition of mitochondrial oxygen consumption rates (OCR) and
ATP production, in all three breast cancer cell lines tested, at a level of 500 nM. However,
basal glycolytic rates in MCF7 and MDA-MB-468 cells remained unaffected at levels of
MTDR of up to 1 mM. We conclude that MTDR can be used to specifically target and
eradicate CSCs, by selectively interfering with mitochondrial metabolism, by employing
nano-molar concentrations of this chemical entity. In further support of this notion, MTDR
significantly inhibited tumor growth and prevented metastasis in vivo, in a xenograft model
employing MDA-MB-231 cells, with little or no toxicity observed. In contrast, Abemaciclib,
an FDA-approved CDK4/6 inhibitor, failed to inhibit metastasis. Therefore, in the future,
MTDR could be modified and optimized via medicinal chemistry, to further increase itsJuly 2021 | Volume 11 | Article 6783431
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their eradication.Keywords: MitoTracker Deep Red (MTDR), near-infrared dyes (NIR), cancer stem-like cells (CSCs), mitochondria,
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Cancer stem-like cells (CSCs) are a relatively small sub-
population of tumor cells that share characteristic features with
normal adult stem cells and embryonic stem cells (1–4). As such,
CSCs are thought to be a ‘primary biological cause’ for i) tumor
regeneration and ii) systemic organismal spread, resulting in the
clinical features of tumor recurrence and distant metastasis,
ultimately driving treatment failure and premature death in
cancer patients undergoing chemo- and radio-therapy (1, 2, 4, 5).
Evidence indicates that CSCs also function in tumor
initiation, as isolated CSCs experimentally behave as tumor-
initiating cells (TICs) in pre-clinical animal models (1, 2). As
approximately 90% of all cancer patients die pre-maturely from
metastatic disease world-wide (4), there is a great urgency and
unmet clinical need, to develop novel therapies for effectively
targeting and eradicating CSCs. Most conventional therapies do
not target CSCs and often increase the frequency of CSCs, in the
primary tumor and at distant sites.
One new approach to the elimination of CSCs has been
through the exploitation of cellular metabolism (4). As CSCs
are amongst the most energetic cancer cells, new metabolic
inhibitors could be employed to induce ATP depletion to
“starve” CSCs to death (4–7). So far, we have identified
numerous FDA-approved drugs with off-target mitochondrial
side effects that have anti-CSC properties and induce ATP
depletion, including the antibiotic Doxycycline, which
functions as an inhibitor of mitochondrial protein translation
(5). Doxycycline, a long-acting Tetracycline analogue, is
currently used for treating diverse forms of infections, such as
acne, acne rosacea, and malaria prevention, amongst others. In a
recent Phase II clinical study, pre-operative oral Doxycycline
(200 mg/day for 14 days) reduced the CSC burden in early breast
cancer patients between 17.65% and 66.67%, with a near 90%
positive response rate (8).
Therefore, it is imperative that we identify other complementary
approaches with higher potency, to metabolically starve CSCs by
targeting mitochondria and driving ATP depletion. Previous
studies have shown that, in general, cyanine dyes accumulate in
cells derived from solid tumors, e.g., prostate (9), gastric (10),
kidney (11), hepatocytes (12, 13), lung (14) and glioblastoma (15),
but not in healthy cells in vitro (16–20). More specifically, they
observed that cyanine dyes preferentially target mitochondria in
cancer cells, by generating a selective chemically-induced
cytotoxicity, through redox-based mechanisms (21). In addition,
in vivo experiments have shown that NIR cyanine derivatives
(e.g. IR-780) in general are safe to use, with short-term
accumulation and a serum half-life of minutes to hours (22),
whereas, in tumors its fluorescent signal persists for days in
animals. In addition, they observed that the thiol reactive chloro-2
methyl moiety (meso-chlorine-group) increased IR-780 tumor
localization in vivo. Therefore, these compounds have been used
mainly for theranostic approaches, as well as for photodynamic and
photothermal therapy (17, 23–25).
Here, we propose to repurpose the heptamethine cyanine dye
MitoTracker Deep Red (MTDR) as a potential therapeutic for
targeting mitochondrial metabolism in CSCs. MTDR is currently
used as a non-toxic fluorescent chemical probe with a thiol
reactive chloromethyl-moiety for visualizing, in the long term,
the distribution of mitochondria in living cells and, in the short
term, to quantitate mitochondrial potential by FACS or
fluorescent microscopy analysis. Recent evidence also indicates
that MTDR can also be used as a marker to purify drug-resistant
CSC activity by flow-cytometry (26, 27), which was validated by
other functional assays, including pre-clinical animal models that
documented higher tumor-initiating activity in vivo (26).
In the current work, we investigated the anti-cancer
properties of MTDR and other NIR dyes, namely HITC, DDI,
and IR-780. Interestingly, we found that MTDR, HITC and DDI
were all effective inhibitors of anchorage-independent CSC
propagation. However, IR-780 had no significant effect in the
nanomolar range. In addition, we tested seven Cyanine 5 (Cy5)
heptamethine analogs, with different reactive groups, for their
ability to inhibit CSC growth. Overall, we observed that Cy5-
Azide and Cy5-Alkyne are both effective inhibitors of CSCs, in







penta-1,3 dien-1-yl]-1,3,3-trimethyl-3H-indolium chloride) was
purchased from ThermoFisher (# M22426).
Near-Infrared Compounds
HITC iodine (B-1,1’,3,3,3’,3’-Hexamethylindotri-carbocyanine)
(# 252034, Merk), DDI iodine (1,1’Diethyl-2-2’-dicarbo-cyanine)
(# 392197, Merk) and IR780 iodine (2-[2-[2-Chloro-3-[(1,3-
dihydro-3,3-dimethyl-1-propyl-2H-indol 2ylidene)ethylidene]-
1-cyclohexen-1-l] ethenyl] -3,3-dimethyl-1 propylindolium
iodide) (# 425311, Merk). To prepare a 10 mM stock solution
all NIR compounds were first dissolved in PBS, DMEMwith 10%
FBS, DMEM/F-12. DDI and HITC were dissolved best in water,
whereas IR780 in DMEMmedia (10% FBS). All compounds wereJuly 2021 | Volume 11 | Article 678343
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filtered using a 0.02 μm filter, prior to treating cells. Stock
solutions were kept at -20°C.
Cy5 Analogs
Cy5 analogs were purchased from Lumiprobe (Cyanine5 NHS
ester (#13020), Cyanine5 Maleimide (#13080), Cyanine5 Azide
(#A3030), Cyanine5 Alkyne (#A30B0), Cyanine5 Hydrazide
(#13070), Cyanine5 Amine (#130C0), Cyanine5 Carboxylic
Acid (#13090). All Cy5 compounds were dissolved at 10 mM
in DMSO and stored at -20°C.
Cell Lines
Human breast cancer cell lines (MCF7, MDA-MB-231 and
MDA-MB-468) were all obtained from the American Type
Culture Collection (ATCC).
3D-Mammosphere Formation
A single cell suspension was prepared using enzymatic (1x
Trypsin-EDTA, Sigma Aldrich, cat. #T3924), and manual
disaggregation (25-gauge needle). Five thousand cells were
plated with in mammosphere medium (DMEM-F12/B27/20ng/ml
EGF/PenStrep), under non-adherent conditions, in six wells plates
coated with 2-hydroxyethylmethacrylate (poly-HEMA, Sigma, cat.
#P3932). Cells were grown for 5 days and maintained in a
humidified incubator at 37°C at an atmospheric pressure in 5%
(v/v) carbon dioxide/air. After 5 days, 3D mammospheres with a
diameter greater than 50-μm were counted using a microscope,
fitted with a graticule eye-piece, and the percentage of cells which
formed spheroids was calculated and normalized to one (1 = 100%
MFE; mammosphere forming efficiency). Mammosphere assays
were performed in triplicate and repeated three times independently.
Metabolic Flux Analysis on the Total
Cell Population
Extracellular acidification rates (ECAR) and oxygen consumption
rates (OCR) were analyzed using the Seahorse XFe96 analyzer
(Agilent/Seahorse Bioscience, USA). Cells were maintained in
DMEM supplemented with 10% FBS (fetal bovine serum), 2 mM
GlutaMAX, and 1% Pen- Strep. Twenty-thousand breast cancer cells
were seeded per well, into XFe96-well cell culture plates, and
incubated at 37°C in a 5% CO2 humidified atmosphere. After 24-
48 hours, MCF7 cells were washed in pre-warmed XF assay media, as
previously described. ECAR and OCR measurements were
normalized for cell protein content, by the SRB colorimetric assay.
Data sets were analyzed using XFe96 software and Excel software.
Measuring the Metabolic Effects of MTDR
in a CSC-Enriched MCF7 Cell Population
To quantitatively measure the mitochondrial-specific effects of
MTDR on a CSC-enriched cell population, we used the Seahorse
XFe96 Analyzer to perform the XF Cell Mito Stress Test. Briefly,
MCF7 cells were seeded for 3D-mammosphere formation and
were grown for 5-days using the standard protocol, but in the
absence or presence of MTDR at a low concentration (100 nM),
to avoid cell death. Then, the resulting 3D-mammospheres were
collected, dissociated into single cells by incubation with trypsinFrontiers in Oncology | www.frontiersin.org 3(for 10 minutes at 37°C) and passage through a syringe. The
single cell suspension was then passed through a 40-mm strainer,
to remove potentially aggregated material and then washed with
OCR media. Single cells were counted using Trypan blue to
assess their vitality, prior to metabolic analysis. Then, thirty-
thousand single cells were dispensed into each well of the 96-well
XF microplate pre-coated with Corning™ Cell-Tak Cell and
Tissue Adhesive (Catalog No. CB-40240), to ensure rapid
adhesion of the cells. Finally, the single cells were briefly
centrifuged (200 x g for 1 minute) to further ensure their
attachment to the bottom of the wells. Finally, OCR was
measured using the Seahorse Metabolic Flux Analyser (XFe96),
under standard conditions at 37°C.
Cell Viability Assays
The effects of MTDR on cell viability were measured by staining
cell monolayers with the nuclear fluorescent dye Hoechst 33342,
which labels DNA in living cells. Quantitation was performed
using a Varioskan LUX multimode microplate reader. The
treatment was conducted for 72 hours prior to microplate analysis.
Fluorescent Microscopy Analysis
Microscopy analysis was performed by analyzing samples in live
cell imaging with EVOS imaging platform (ThermoFisher) using
the Cy5 channel and bright field.
Tumor Growth, Metastasis and Embryo
Toxicity Assays
Xenograft studies were performed, essentially as previously
described (28). According to the French legislation, no ethical
approval is needed for scientific experimentation using oviparous
embryos (decree n° 2013–118, February 1, 2013; art. R-214–88).
Animal studies were performed under animal experimentation
permit N° 381029 and B3851610001 to Jean Viallet
(INOVOTION). Briefly, fertilized White Leghorn eggs were
incubated at 37.5°C with 50% relative humidity for 9 days. At
that moment (E9), the chorioallantoic membrane (CAM) was
dropped down by drilling a small hole through the eggshell into
the air sac, and a 1 cm² window was cut in the eggshell above the
CAM. For amplification and grafting of the tumor cells, the MDA-
MB-231 tumor cell line was cultivated in DMEM supplemented
with 10% FBS and 1% penicillin/streptomycin. On day E9, MDA-
MB-231 cells were trypsinized, washed with complete medium and
suspended in graft medium. More specifically, we applied Corning®
Matrigel® Matrix (Catalogue number: 354230) for tumor cell
xenografting. This was performed because it has been
demonstrated that the increased viscosity of the cell suspension
can prevent the diffusion of cells at the injection site. Briefly, tumor
cells are suspended in Matrigel diluted with complete media at 1:1
ratio and then grafted in 50 μl/egg. For the MDA-MB-231 tumor
model, an inoculum of 1 x 106 cells in 50μL (i.e., 25 μl Matrigel +
25μl complete culture media) was added onto the CAM of each egg
at E9. On day E10, tumors were detectable, and they were then
treated daily for 8 days with vehicle alone (1% DMSO in PBS) or
with different dosages of MTDR. The therapeutic solution was
added dropwise onto the tumor. At day 18 (E18), the upper portion
of the CAM was removed from each egg, washed in PBS and thenJuly 2021 | Volume 11 | Article 678343
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weighed. For tumor growth assays, at least 10 tumor samples were
collected and analyzed per group (n ≥ 10). On day E18, a 1 cm²
portion of the lower CAM was collected to evaluate the number of
metastatic cells in 7 to 8 samples per group (n ≥ 7). Genomic DNA
was extracted from the CAM (commercial kit) and analyzed by
qPCR with specific primers for Human Alu sequences. Calculation
of Cq for each sample, mean Cq and relative amounts of metastases
for each group were directly managed by the Bio-Rad® CFX
Maestro software. A one-way ANOVA analysis with post-tests
was performed on all the data. To measure embryo tolerability,
before each administration, the treatment toxicity was evaluated by
scoring the number of dead embryos.
Statistical Significance
The statistical tests used were the unpaired Student’s t-test and one-
way ANOVA. Bar graphs are shown as the average ± SEM (standard
error of the mean). A p-value of less than 0.05 was considered
statistically significant and is indicated by asterisks: *p < 0.05, **p <
0.01, ***p < 0.001 and ****p < 0.0001. ns, not significant.
Software
All statistical analysis was performed using GraphPad version 8. All
compounds chemical structures were drawn by using ChemDraw 18.Frontiers in Oncology | www.frontiersin.org 4RESULTS
Here, we directly assessed the suitability of using MitoTracker
Deep Red (MTDR), a well-known mitochondrial fluorescent
probe, for targeting mitochondria and effectively inhibiting the
propagation of breast CSCs. For this purpose, we employed three
model cell lines of breast cancer: MCF7, MDA-MB-231, MDA-
MB-468, as well as an hTERT-BJ1 skin fibroblasts cell line.
MCF7 is an ER (+) breast cancer cell line, while MDA-MB-
231 and MDA-MB-468 are both triple negative [ER (-), PR (-),
HER2 (-)] cell lines. In this context, we assessed the targeted
effects of MTDR on 3D CSC propagation and overall metabolic
rates in 2D monolayer cultures.
The structure of MTDR is shown in Figure 1A.
MTDR Inhibits the 3D Anchorage-
Independent Propagation of CSCs
In order to assess the effects of MTDR on CSC propagation, we
used the mammosphere assay as a functional readout of
“stemness” and 3D anchorage-independent growth. As CSCs
are highly-resistant to many types of cell stress, they can undergo
anchorage-independent propagation, under low-attachment
conditions. Ultimately, this results in the generation of >50 mm
sized 3D spheroid-like structures. These “mammospheres” are
highly enriched in CSCs and progenitor-like cells, andA B
DC
FIGURE 1 | MTDR inhibits mammosphere formation in MCF7, MDA-MB-231 and MDA-MB-468 cells. (A) Structure of MitoTracker Deep Red FM (MTDR). MTDR is
a far-red fluorescent dye that stains active mitochondria. Note that MTDR is a lipophilic cation, which is a chemical characteristic that results its high-efficiency
targeting to mitochondria. (B) Effects of MTDR on 3D mammosphere formation in MCF7 cells. Note that MTDR inhibits 3D anchorage-independent growth in MCF7
cells, with an IC-50 of <100 nM. (C) Effects of MTDR on 3D mammosphere formation in MDA-MB-231 cells. Note that MTDR inhibits 3D anchorage-independent
growth in MDA-MB-231 cells, with an IC-50 between 100 and 500 nM. (D) Effects of MTDR on 3D mammosphere formation in MDA-MB-468 cells. Note that MTDR
inhibits 3D anchorage-independent growth in MDA-MB-468 cells, with an IC-50 between 50 and 100 nM. The statistical test used was a one-tail unpaired t-test.July 2021 | Volume 11 | Article 678343
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development, a solid “ball” of cells without a hollow lumen.
Under these culture conditions of non-attachment, the majority
of epithelioid cancer cells die, via an unusual form of apoptosis,
known as “anoikis” (29).
Remarkably, each single 3D mammosphere is constructed
from the anchorage-independent clonal propagation of an
individual CSC, and does not involve the process of self-
aggregation, under these limiting dilution conditions. As a
consequence, the growth of 3D spheroids provides functional
culture conditions to select for a population of epithelioid CSCs,
with EMT properties. As such this provides an ideal assay for
identifying small molecules that can target the anchorage-
independent growth of CSCs.
Figure 1B shows that MTDR potently inhibits 3D spheroid
formation in MCF7 cells, with an IC-50 of less than 100 nM.
Similarly, MTDR also inhibited the anchorage-independent
growth of MDA-MB-231 cells, in the range of 100 to 500 nM
(Figure 1C). Finally, MTDR inhibited 3D sphere formation in
MDA-MB-468 cells, with an IC-50 of approximately 50 nM
(Figure 1D). Therefore, MTDR is clearly effective in targeting
CSCs, in both ER (+) and triple-negative breast cancer-derived
cell lines, in the nano-molar range.Frontiers in Oncology | www.frontiersin.org 5MTDR Specifically Inhibits
Mitochondrial Metabolism
To validate the idea that MTDR was specifically targeting
mitochondrial metabolism, we next subjected monolayer
cultures to metabolic flux analysis, using the Seahorse
XFe96 analyzer.
Figures 2, 3 and Supplemental Figure S1 show the effects of
MTDR on the mitochondrial oxygen consumption rate (OCR) in
MCF7, MDA-MB-231 and MDA-MB-468 monolayer cells,
respectively. In all three cell lines, MTDR treatment induced
near complete inhibition of mitochondrial basal and maximal
respiration and ATP production, starting at a concentration of
500 nM.
The extracellular acidification rate (ECAR), a measure of
glycolytic function, remained largely unchanged in MCF7 and
MDA-MB-468 cell monolayers, at levels of MTDR of up to 1 μM.
Similarly, in MDA-MB-231 cells, the levels of glycolysis remained
unchanged from 1 nM to 100 nM MTDR, but glycolysis was
decreased at levels of 500 to 1,000 nM, especially for glycolytic
reserve (Figures 4, 5 and Supplemental Figure S2). Therefore,
high nano-molar concentrations of MTDR, of 500 nM or greater,
preferentially affected mitochondrial metabolism in all three
breast cancer cell lines tested.FIGURE 2 | MTDR potently inhibits the mitochondrial oxygen consumption rate (OCR) in MCF7 cells. A representative Seahorse tracing is shown, with bar graphs
highlighting the quantitative, dose-dependent effects of MTDR on basal respiration, maximal respiration and ATP production. Note that MTDR treatment exhibits near
complete inhibition of OCR in MCF7 cells at 500 nM. The statistical test used was a one-tail unpaired t-test.July 2021 | Volume 11 | Article 678343
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in a CSC-Enriched MCF7 Cell Population
To further evaluate the metabolic effects of MTDR, we measured
the mitochondrial-specific effects of MTDR on a CSC-enriched
MCF7 cell population, using the Seahorse XFe96 Analyzer to
perform the XF Cell Mito Stress Test.
Briefly, MCF7 cells were seeded for 3D-mammosphere
formation and were grown for 5-days using the standard
protocol, but in the absence or presence of MTDR at a lower
concentration (100 nM), to avoid cell death. Then, the resulting
3D-mammospheres were collected, dissociated into single cells
and subjected to OCR analysis.
Figure 6 shows that at a concentration as low as 100 nM,
MDTR significantly inhibited OCR in this CSC-enriched MCF7
cell population. Under these conditions, mitochondrial ATP
production was reduced by nearly 50%.
MTDR Preferentially and Selectively
Targets Cancer Cells
To examine the selectivity of MTDR for the preferential targeting
of cancer cells, we used a Hoechst-based viability assay. Briefly,
MCF7, MDA-MB-231 and MDA-MB-468 cell monolayers were
all treated with MTDR, at concentrations ranging from 1 nM to
1 mM, for a period of 72 hours and their viability was assessed
using Hoechst 33342, a nuclear dye that stains DNA in live cells.Frontiers in Oncology | www.frontiersin.org 6The viability of normal human fibroblasts (hTERT-BJ1) treated
with MTDR was also assessed in parallel. Quantitation was
performed with a plate-reader.
Figure 7 shows that MTDR more effectively killed MCF7,
MDA-MB-231 and MDA-MB-468, but was less effective on
hTERT-BJ1 (a non-transformed fibroblast cell line). Therefore,
MTDR was more potent and selective for the targeting of breast
cancer cells, with little or no effect on normal fibroblast viability.
MCF7 Treatment With Other Near-Infrared
(NIR) Compounds
To evaluate the anti-cancer properties other carbocyanine dyes
with similar spectral emission as MTDR, we next selected three
compounds with a spectral emission in the NIR range (Figures 8
and 9) and performed the MCF7 3D-mammosphere assay to
assess their effect on CSC propagation. Namely, HITC, DDI and
IR-780 were all tested, using the same nanomolar concentration
range used for MTDR.
Figure 9 illustrates that both HITC and DDI significantly
inhibited CSC propagation, between 100 and 1,000 nM. In
contrast, IR-780, was not effective. In support of these findings,
Figure 8 shows that only HITC and DDI were efficiently
incorporated into 3D-mammospheres, while IR780 was not
taken up by MCF7 CSCs, at concentrations in the nano-
molar range.FIGURE 3 | MTDR potently inhibits the mitochondrial OCR in MDA-MB-231 cells. A representative Seahorse tracing is shown, with bar graphs highlighting the
quantitative, dose-dependent effects of MTDR on basal respiration, maximal respiration and ATP production. Note that MTDR treatment exhibits near complete
inhibition of OCR in MDA-MB-231 cells at 500 nM. The statistical test used was a one-tail unpaired t-test.July 2021 | Volume 11 | Article 678343
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respiration and aerobic glycolysis, we treated adherent MCF7
and then measured their OCR and ECAR. Supplemental Figure S3
shows that basal and maximal OCR, as well as ATP production
levels, were both significantly inhibited, as compared to vehicle-
alone control cells. In contrast, ECAR levels were increased
significantly, at 500 and 1,000 nM (Supplemental Figure S4).
Surprisingly, DDI did not affect OCR and ECAR in MCF7 cells
(Supplemental Figures S5, S6).
In summary, our results indicate that HITC specifically
targets mitochondrial metabolism and inhibits 3D-
mammosphere formation. In contrast, DDI also inhibits 3D-
mammosphere formation, but by a mitochondrial-independent
mechanism. Finally, IR780 did not inhibit CSC propagation in
the nanomolar range.
MCF7 Treatment With Cyanine 5 (Cy5)
Analogs
To assess the possible anti-cancer properties of Cy5 lipophilic
fluorophores, we next tested the potential inhibitory activity of
seven commercially available Cy5 analogs (Figure 10).
We found that Cy5-Azide and Cy5-Alkyne analogs were the
only two compounds out of seven, to significantly inhibit MCF7
3D-mammosphere formation, between 500 nM to 1,000 nM
(Figure 11). However, all the Cy5 analogs were internalized by
mammospheres, at low nanomolar concentrations (50 nM),Frontiers in Oncology | www.frontiersin.org 7independently from their anti-CSC effects, and suggesting that
Cy5 retention lasts for days in CSCs (Supplemental Figure S7).
Furthermore, we found that both carbocyanine compounds
(Cy5-Azide and Cy5-Alkyne) are mitochondrial OXPHOS
inhibitors that act, in the range of 500 nM and 1000 nM, and
they induce glycolysis to compensate for mitochondrial ATP
depletion (data not shown).
MTDR Potently Inhibits Cancer Cell Tumor
Growth and Metastasis In Vivo
To determine the potential therapeutic effects of MTDR in vivo,
we next used a human breast cancer cell line, namely MDA-MB-
231 cells, and the well-known chorio-allantoic membrane
(CAM) assay in chicken eggs, to evaluate the effects of MTDR
on tumor growth and metastasis (28, 30).
More specifically, an inoculum of 1 x 106 MDA-MB-231 cells
was added on top of the Upper CAM of each egg (day E9). On
day E10, tumors were detectable and they were then treated daily
for 8 days with vehicle alone (1% DMSO in PBS) or MTDR. After
8 days of MTDR administration, on day E18 all tumors were
weighed, and the Lower CAM was collected to evaluate the
number of metastatic cells, as analyzed by qPCR with specific
primers for Human Alu sequences.
Figure 12 shows the effects of MTDR onMDA-MB-231 tumor
growth. Note that MTDR showed a significant effect on tumor
growth, with inhibition of up to nearly 30%, as a result of theFIGURE 4 | MTDR has no effect on glycolysis in MCF7 cells. A representative Seahorse tracing is shown, with bar graphs highlighting the quantitative, dose-
dependent effects of MTDR on glycolysis, glycolytic capacity and glycolytic reserve. Note that MTDR has no significant effect on glycolysis, at concentrations up to
1 mM. The statistical test used was a one-tail unpaired t-test.July 2021 | Volume 11 | Article 678343
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significant effects on MDA-MB-231 cancer cell metastasis.
Figure 13 illustrates that MTDR inhibited metastasis (by >60%)
at the same concentrations tested. Interestingly, the effects of
MTDR on metastasis were significantly more pronounced.
Surprisingly, little or no embryo toxicity was observed for
MTDR (Figure 14). Therefore, we conclude that MTDR can be
further developed as an anti-cancer agent, for inhibiting both
tumor growth andmetastasis, without showing significant toxicity.
Abemaciclib, a CDK4/6 Inhibitor, Does Not
Prevent Metastasis In Vivo
For comparison purposes, in parallel, we also assessed the
functional activity of an FDA-approved CDK4/6 inhibitor,
namely Abemaciclib, which was developed by Eli Lilly.
Abemaciclib was first approved in 2017, with breakthrough
status, for the treatment of breast cancer patients with advanced
or metastatic disease. Results from the MONARCH 3 clinical trial
indicated that there was significant clinical benefit for progression-
free survival (28.18 versus 14.76 months; hazard ratio [95%
confidence interval], 0.540 [0.418–0.698]; p = .000002). As a
consequence, Abemaciclib is considered standard-of-care for
patients with advanced or metastatic breast cancer (31).
Therefore, here we evaluated the efficacy of Abemaciclib,
using the CAM assay, to measure its effects on MDA-MB-231
tumor growth, metastasis and embryo toxicity.Frontiers in Oncology | www.frontiersin.org 8Interestingly, treatment with Abemaciclib (in a similar
concentration range as with MTDR) resulted in the significant
inhibition of tumor growth by up to 47%, at a 90 mM
(Figure 15A). Importantly, little or no embryo toxicity was
observed in this concentration range (Figure 15B). However,
Abemaciclib was completely ineffective for the prevention of
metastasis (Figure 15C).
Thus, as compared with the standard-of-care for advanced
breast cancer (Abemaciclib), MTDR was clearly more effective
for the prevention of metastatic dissemination, using MDA-MB-
231 cells (Figure 13).DISCUSSION
MTDR is a carbocyanine-based fluorescent probe that
chemically behaves as a lipophilic cation. MTDR is
functionally localized to mitochondria and is normally used to
measure mitochondrial mass in living cells, by fluorescence
microscopy and/or FACS analysis. Here, we assessed whether
MTDR could be used to target mitochondria in CSCs, to prevent
their anchorage-independent propagation. For this purpose,
we used three independent breast cancer cell lines, namely
MCF7, MDA-MB-231 and MDA-MB-468 cells, representing
both ER(+) and triple-negative breast cancer sub-types.
Remarkably, we observed that MTDR potently inhibited theFIGURE 5 | MTDR has minor effects on glycolysis in MDA-MB-231 cells. A representative Seahorse tracing is shown, with bar graphs highlighting the quantitative,
dose-dependent effects of MTDR on glycolysis, glycolytic capacity and glycolytic reserve. Note that MTDR has no significant effect on glycolysis, at concentrations
up to 100 nM. Mild to moderate inhibition of glycolysis was only observed, starting at 500 nM. The statistical test used was a one-tail unpaired t-test.July 2021 | Volume 11 | Article 678343
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molar concentrations of the near-infrared fluorescent probe.
Furthermore, we directly validated that MTDR specifically
targeted mitochondrial metabolism and induced ATP
depletion, by using the Seahorse XFe96 metabolic flux
analyzer. However, we did not see a significant induction of
glycolysis by MTDR, in all three cell lines.
Originally, it was thought that MTDR could be used as a probe
to measure mitochondrial mass, independently of mitochondrial
activity or membrane potential. However, recent experiments
directly show that MTDR staining is prevented and/or reduced
by treatment with FCCP (carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone), a potent mitochondrial uncoupling agent (32).
Therefore, MTDR may preferentially accumulate in highly-active
mitochondria, potentially making it a better therapeutic drug for
targeting and inhibiting mitochondrial function.
In addition, we found that other NIR compounds such as
HITC and DDI, but not IR780, accumulate in MCF7 cells and
inhibit CSC anchorage-independent growth. Our results
demonstrated that HITC effectively blocks CSCs growth in a
mitochondrial-dependent manner, and induces glycolysis
starting at 500 nM. In contrast, we showed that DDI, did not
produce any noticeable metabolic effects, but was able to inhibit
CSC growth in the nanomolar range in MCF7 cells.
Furthermore, we showed that IR-780 was not effective against
CSCs growth and was not internalized by tumor cells, atFrontiers in Oncology | www.frontiersin.org 9nanomolar concentrations. Thereafter, we compared seven Cy5
carbocyanine analogs with different reactive groups for their
ability to inhibit MCF7 CSC growth. Our results showed that all
compounds tested were internalized after five days of treatment
(Supplemental Figure S7). However, only Cy5-Alkyne and Cy5-
Azide blocked 3D mammosphere growth and also targeted
energized mitochondria in cancer cells (data not shown)
within the nanomolar range, which is line with previous
studies (33).
We have previously shown that other lipophilic cations, such
as derivatives of triphenyl-phosphonium (TPP) (34), can be
effectively used to target mitochondria in CSCs, significantly
preventing 3D mammosphere formation. However, these TPP
derivatives were much less potent, inhibiting 3D spheroid
formation in MCF7 cells, with an IC-50 between 500 nM to 5 mM.
Therefore, MTDR is clearly more potent than these TPP-
derivatives, such as 2,4-dichlorobenzyl-TPP, 1-naphthylmethyl-
TPP, 3-methylbenzyl-TPP, 2-chlorobenzyl-TPP, and 2-butene-
1,4-bis-TPP. As such, MTDR, HITC, Cy5-Alkyne and Cy5-Azide
are clearly more efficacious.
Interestingly, in our work, we identified four carbocyanines that
target mitochondria (MTDR, HITC, Cy5-Alkyne and Cy5-Azid)
and we found that DDI did not target mitochondria, but it showed
the same potency in inhibiting CSC growth. In contrast, IR-780 at
nanomolar concentrations, was not internalized and this is in line
with previous in vitro studies (23). The fact that IR-780 atFIGURE 6 | MTDR potently inhibits the mitochondrial OCR in a CSC-enriched MCF7 cell population. A representative Seahorse tracing is shown, with bar graphs
highlighting the quantitative effects of MTDR on basal respiration, maximal respiration and ATP production. Note that MTDR treatment exhibits inhibition of OCR at
100 nM. Briefly, MCF7 cells were seeded for 3D-mammosphere formation and were grown for 5-days using the standard protocol, but in the absence or presence
of MTDR at a lower concentration (100 nM), to avoid cell death. Then, the resulting 3D-mammospheres were collected, dissociated into single cells and subjected to
OCR analysis. Under these conditions, mitochondrial ATP production was reduced by nearly 50%. The statistical test used was a one-tail unpaired t-test.July 2021 | Volume 11 | Article 678343
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35), highlights that MTDR, HITC, Cy5-Alkyne and Cy5-Azide are
all more effective in eradicating CSCs than IR-780.
In principal, “energized” cancer cell mitochondria present a
higher membrane potential (about ~60 mV more negative than
in normal cells) (36). Therefore, mitochondria in cancer cells
produce more ATP and play a key role for CSC metastatic
growth. Indeed, our results are in line with the general theory
that CSC strictly depend on mitochondria. We report that in our
experiments that glycolysis alone was not sufficient to allow for
3D mammosphere formation, when OCR was targeted by
carbocyanines in breast cancer cells. We speculate, as
previously demonstrated elsewhere (21), that the lipophilic
carbocyanine mechanism of action is through chemical
alkylation between electrophilic carbocyanines and nucleophilic
atoms within cysteine residues found in mitochondrial proteins
(chemical intoxication). In addition, the low pH of the
mitochondrial matrix increases chemical alkylation reactions
that generate electrophile-protein adducts that are toxic to
tumor cells. Therefore, one can speculate that this “non-
selective”, chemical intoxication by carbocyanines would
presumably allow the avoidance of possible resistance to such
broad, but yet organelle-specific, intoxication of cancer
cell mitochondria.Frontiers in Oncology | www.frontiersin.org 10Indeed, after observing the Cy5-Alkyne mitochondrial-
dependent inhibition of breast CSCs, the same analog was
found to show anti-tumor effect, both in in vitro and in vivo,
in the nanomolar range (33), further confirming our findings.
Interestingly, Cy5-NHS was found to successfully deliver nano-
particles and other compounds such as doxorubicin to
mitochondria, and to retain their mitochondrial targeting of
tumor cells. Furthermore, in other in vivo studies, they found
that carbocyanines have a strong safety profile, with low toxicity
and fast clearance as theranostic agents, and are considered non-
toxic agents for cell live imaging applications in vitro (17).
Furthermore, acute toxicity studies conducted on mice using
100 nM concentrations of IR-780 demonstrated no acute
toxicity, and low organ accumulation was observed (25).
Lipophilic carbocyanine uptake has been found to depend on
the Organic Anionic Transporter Protein (OATP) family of
transporters (37). OATP transporters function as non-selective
sodium-independent co-transporter proteins that regulate the
flux of ions and small molecules across the plasma membrane of
the cell (e.g., bile salts, bilirubin, steroids and thyroid hormones)
(38). OATP transporters influx of small molecules is coupled to
the passive efflux of intracellular bicarbonate, glutathione and
glutathione adducts. Interestingly, the OATP1B3 isoform was
previously described to selectively transport Cy5.5, IR-780 as wellFIGURE 7 | MTDR preferentially and selectively targets cancer cells. MCF7, MDA-MB-231 and MDA-MB-468 cell monolayers were all treated with MTDR for a
period of 72 hours and viability was assessed using Hoechst 33342, a nuclear dye that stains DNA in live cells. Effects of MTDR on the viability in normal human
fibroblasts (hTERT-BJ1) were assessed in parallel. Note that MTDR effectively killed MCF7, MDA-MB-231 and MDA-MB-468 cells, but had little or no effect on
normal cell viability (hTERT-BJ1), in the same concentration range. Therefore, MTDR was more potent and selective for the targeting of breast cancer cells, relative to
normal fibroblasts. The statistical test used was a one-tail unpaired t-test.July 2021 | Volume 11 | Article 678343
Sargiacomo et al. MTDR Eradicates Cancer Stem CellsFIGURE 8 | Structure and uptake of NIR compounds in MCF7 cells. (Left). Near-infrared (NIR) compounds. Chemical structures of HITC (B-1,1’,3,3,3’,3’-
Hexamethylindotricarbocyanine iodide), DDI (1,1’Diethyl-2-2’-dicarboccyanine iodide) and IR780 (2-[2-[2-Chloro-3-[(1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-
ylidene)ethylidene]-1-cyclohexen-1-l]ethenyl]-3,3-dimethyl-1-propylindolium iodide). NIR compounds present a characteristic peak fluorescent emission in the NIR
light spectrum. (Middle and Right). MCF7 mammosphere cellular uptake. Treatment of mammospheres using 50 nM and 1000 nM concentrations of HITC, DDI and
IR780 for five days. Note that HITC and DDI is localized within the cell and was observed with the Cy5 channel (near infrared signal), whereas IR780 cellular uptake
was not detectable, even at higher concentrations.FIGURE 9 | HITC and DDI behave as cancer stem cell inhibitors. Non-adherent MCF7 cells were treated using different drug concentrations of HITC, DDI and IR780
(1, 50, 100, 500, 1,000 nM) for five days and then mammospheres were counted. Data are expressed as fold increase Vs control. Statistical analysis was conducted
using one-way ANOVA.Frontiers in Oncology | www.frontiersin.org July 2021 | Volume 11 | Article 67834311
Sargiacomo et al. MTDR Eradicates Cancer Stem Cellsas Cy5-Alkyne heptamethine carbocyanines both in vitro and
in vivo (37, 39–42). Furthermore, OATPs expression in cells was
found to be induced by hypoxia, i.e., lowering oxygen conditions
or inducing pseudo-hypoxia via DMOG (dimethyloalyglycine)
treatment. OATP expression is positively regulated by the
transcription factor of hypoxia induction factor 1 (HIF1a).
Therefore, cellular hypoxia increases carbocyanine uptake in
tumor cells via OATP (33, 42), suggesting that hypoxic cancer
cells would be more susceptible to carbocyanines, as compared to
normoxic cells, and can be preferentially eliminated by using
mitochondrially-targeted carbocyanine dyes.
The de novo expression of OATP1B3 and 1B1, in general, is
considered specific for the liver, but it was found to increase in
several tumors. In breast cancer tissue, as well as other cells lines,
OATP1B3 transporters are upregulated (38). However, in
normal breast tissue, it is absent. Hence, we believe that
carbocyanine absorption could depend on OATP functionalFrontiers in Oncology | www.frontiersin.org 12expression also for breast CSCs. Therefore, in addition to
carbocyanine’s chemical electrophilic properties previously
discussed, we must consider the key role of OATP in
carbocyanines uptake by CSCs. As far as we are aware, OATP
expression has not been examined in CSCs and should be
further investigated.
Thiol reactive groups are present in both MTDR and IR-780
carbocyanine structures and are thought to react with cysteine
residues through meso-chlorine motility inside their chemical
structure. Nevertheless, we observed that MTDR, compared to
IR-780, was more potent in mitochondrial inhibition. A possible
explanation is that IR-780 is a Cy7, whereas MTDR is Cy5
member, indicating specific chemical differences between
carbocyanine families regarding their potential anti-tumor
properties. Nevertheless, Cy7 compounds, such as HITC, goes
against such a hypothesis as it blocked mitochondrial respiration
in the nanomolar range, and it is a heptamethine without meso-FIGURE 10 | Cyanine 5 structure and analogue structures. Upper: The chemical structure of cyanine 5 compounds is characterized by a polymethine bridge in
between the two nitrogen atoms. The positive charge (+) is delocalized within the scaffold on one of the two amine groups (N+). The amine group can be used to
attach several different side chains (R1-7). Lower: Below are different Cyanine 5 analogue with their side chain structure highlighted.July 2021 | Volume 11 | Article 678343
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Frontiers in Oncology | www.frontiersin.orgFIGURE 11 | Effects of Cyanine 5 on 3D mammosphere formation in MCF7 cells. MCF7 mammospheres cells were treated with different concentrations of each
compound (1, 50, 100, 500 and 1,000 nM) for five days. Mammospheres >50-µm were counted manually using a bright field microscope (n = 4). Data is expressed
as fold increase Vs control. Statistical analysis was conducted using one-way ANOVA.FIGURE 12 | MTDR significantly inhibits tumor growth. MDA-MB-231 cells
and the well-established chorio-allantoic membrane (CAM) assay in chicken
eggs were used to quantitatively measure tumor growth. See Materials &
Methods for specific details. After 8 days of MTDR administration, on day E18
all tumors were weighed. Note that MTDR significantly inhibited tumor growth,
by up to nearly 30%, at a concentration of 75 mM (n ≥ 15). Averages are
shown ± SEM. **p < 0.01; *p < 0.05. Statistical analysis was conducted
using ANOVA.13FIGURE 13 | MTDR preferentially targets and prevent cancer cell metastasis.
MDA-MB-231 cells and the well-established chorio-allantoic membrane
(CAM) assay in chicken eggs were used to quantitatively measure
spontaneous tumor cell metastasis. See Materials & Methods for specific
details. After 8 days of drug administration, the Lower CAM was collected to
evaluate the number of metastatic cells, as analyzed by qPCR with specific
primers for Human Alu sequences. Note that MTDR showed significant
effects on MDA-MB-231 metastasis, with an inhibition of >60%, at a
concentration of 75 mM (n ≥ 7). Averages are shown ± SEM. **p < 0.01.
Statistical analysis was conducted using ANOVA.July 2021 | Volume 11 | Article 678343
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780 and MTDR anti-CSC efficacy may account for other
chemical properties. In addition, an FDA-approved
carbocyanine Indocyanines green (ICG), which is very similar
to IR-780, and is used as an optical marker routinely in the clinic,
is not taken up by tumor cells. One possible explanation that was
advanced is that ICG is missing a thiol reactive group, which is
responsible for IR-780 adduct formation in tumors (22).
In a recent study, human serum albumin (HSA) was found to
bind to IR-780 carbocyanines, via reactive thiol group to albumin
cysteine residues (22), which explains its rapid decrease in the
blood (approximately 30 minutes in the serum for IR-780-like
dies). They found that IR-780 generated a higher fluorescent
signal in the serum compared to ICG (that does not bind to
albumin), and they speculate that IR-780-albumin adducts
increase the half-life and the tumor uptake capacity of
carbocyanines. Interestingly, Usama et al. also reported that
IR-780 albumin-adduct uptake by glioblastoma cells was not
inhibited by BSP, or increased by DMOG (hypoxia inducer).
However, it was abolished only by applying low temperatures
(4°C), which strongly suggests an OATP-independent
mechanism of uptake for IR-780-albumin adducts.
Overall, in this work, we have shown how the energetic state
of malignant cancer cells can be targeted via “tumor-seeking”
drugs, by taking advantage of the chemical properties of
carbocyanine dyes. Hence, we believe that based on our
findings, both in vitro and in vivo, that carbocyanine-induced
mitochondrial cytotoxicity should be generally applicable for
preventing CSC-driven metastatic growth, and could be used as a
preventive treatment against breast cancer relapse, either shortly
after or concurrently with chemo- or radiation therapy.CONCLUSIONS
In conclusion, here we show that MTDR can be used effectively as a
metabolic inhibitor to target mitochondrial function and halt CSC
propagation, in the nano-molar range. The metabolic effects ofFrontiers in Oncology | www.frontiersin.org 14MTDR on mitochondrial OCR and ATP production were directly
validated, using the Searhorse XFe96 flux analyzer. Therefore, we
propose that MTDR, and other related compounds, could beFIGURE 14 | Chick embryo toxicity of MTDR. Note that MTDR was non-
toxic, as compared to the vehicle alone control (n ≥ 17), over a dose range of
25, 50, and 75 mM.A
B
C
FIGURE 15 | Abemaciclib significantly inhibits tumor growth, without preventing
cancer cell metastasis. (A) MDA-MB-231 cells and the well-established chorio-
allantoic membrane (CAM) assay in chicken eggs were used to quantitatively
measure tumor growth. See Materials & Methods for specific details. After 8
days of Abemaciclib administration, on day E18 all tumors were weighed. Note
that Abemaciclib significantly inhibited tumor growth, by nearly 50%, at a
concentration of 90 mM (n > 11). Averages are shown ± SEM. ***p < 0.001.
Statistical analysis was conducted using ANOVA. (B) Note that Abemaciclib was
non-toxic, as compared to the vehicle alone control (n > 15), up to 90 mM.
(C) MDA-MB-231 cells and the well-established chorio-allantoic membrane
(CAM) assay in chicken eggs were used to quantitatively measure spontaneous
tumor cell metastasis. See Materials & Methods for specific details. After 8 days
of drug administration, the Lower CAM was collected to evaluate the number of
metastatic cells, as analyzed by qPCR with specific primers for Human Alu
sequences. Note that Abemaciclib did not show any significant effects on MDA-
MB-231 metastasis, at concentrations up to 90 mM (n = 8). Averages are shown
+ SEM. ns, not significant. Statistical analysis was conducted using ANOVA.July 2021 | Volume 11 | Article 678343
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Supplementary Figure 1 | MTDR potently inhibits the mitochondrial oxygen
consumption rate in MDA-MB-468 cells. A representative Seahorse tracing is
shown, with bar graphs highlighting the quantitative, dose-dependent effects of
MTDR on basal respiration, maximal respiration and ATP production. Note that
MTDR treatment exhibits near complete inhibition of OCR in MDA-MB-468 cells at
500 nM. The statistical test used was an unpaired one-tail t-test.
Supplementary Figure 2 | MTDR has no effect on glycolysis in MDA-MB-468
cells. A representative Seahorse tracing is shown, with bar graphs highlighting the
quantitative, dose-dependent effects of MTDR on glycolysis, glycolytic capacity and
glycolytic reserve. Note that MTDR has no significant effect on glycolysis, at
concentrations up to 1 mM. The statistical test used was an unpaired one-tail t-test.
Supplementary Figure 3 | HITC inhibits mitochondria aerobic respiration.
Adherent MCF7 cells were treated with HITC using five different concentrations for
16 hours. After treatment, the mitochondrial oxygen consumption rate (OCR) was
measured using the Seahorse XFe96 analyzer. Data is expressed as percentage of
OCR vs control. All data was normalized for cell number. Statistical analysis was
conducted using one-way ANOVA.
Supplementary Figure 4 | HITC induces glycolysis. Adherent MCF7 cells were
treated with HITC using five different concentrations for 16 hours. After treatment, the
extracellular acidification rate (ECAR) was measured using the Seahorse XFe96
analyzer. Data is expressed as percentage of ECAR vs control. All data was
normalized for cell number. Statistical analysis was conducted using one-way ANOVA.
Supplementary Figure 5 | DDI does not inhibit mitochondria aerobic respiration.
Adherent MCF7 cells were treated with DDI using five different concentrations for 16
hours and the mitochondrial OCR was measured using the Seahorse XFe96
analyzer. Data is expressed as percentage of OCR vs control. Statistical analysis
was conducted using one-way ANOVA.
Supplementary Figure 6 | DDI does not induce glycolysis. Adherent MCF7 cells
were treated with DDI using five different treatment concentrations, the ECAR was
measured using the Seahorse XFe96 analyzed. Data is expressed as percentage of
ECAR vs control. Statistical analysis was conducted using one-way ANOVA.
Supplementary Figure 7 | Cyanine 5 analog uptake by MCF7 mammospheres.
Microscopy analysis of MCF7 dye internalization at a concentration 50 nM for each
analog was detected in the Cy5 fluorescent channel (red) and is visualized with
nuclear staining detected in the DAPI channel (blue). Images were acquired with an
EVOS fluorescent microscope, using Cy5 channel and a 20x objective.REFERENCES
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